FDG PET-CT在T1部分实性肺腺癌分期中缺乏临床获益
该研究回顾性分析英国两个中心58例放射性疑似T1部分实性肺腺癌患者的FDG PET-CT分期检查,评估淋巴结及转移检出率和治疗管理改变。PET-CT仅使1例患者分期从N0变为N1,未改变任何患者的最终管理。作者认为在该人群中PET-CT额外诊断获益极小,尤其考虑到成本,指南中该适应证的纳入应被重新审视。
要点
- T1部分实性肺腺癌FDG PET-CT分期仅1例由N0改为N1,未改变任何患者管理。
- 作者认为该适应证额外诊断获益极小,尤其考虑到成本。
- 作者提出指南中该适应证的纳入应被重新审视。
核心结论
- 在英国人群中,FDG PET-CT对T1部分实性肺腺癌分期的额外诊断获益极小,未改变最终管理;尤其考虑到成本,指南中该适应证的纳入应被重新审视。
研究设计与样本
- 回顾性研究,来自两个中心,纳入58例放射性疑似T1部分实性肺腺癌患者,评估FDG PET-CT分期检查的淋巴结及转移检出率、管理改变和最终结局。
诊断标准与关键数值
- PET-CT使1例患者分期从N0变为N1,未改变任何患者的最终管理。
临床应用与阅片要点
- 作者认为,尤其考虑到成本,指南中FDG PET-CT用于该适应证的纳入应被重新审视。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
AIM: To assess the rates of nodal and metastatic disease and change in management when staging part-solid T1 lung adenocarcinomas using integrated 2-[18F]-fluoro-2-deoxy-d-glucose (FDG) positron-emission tomography (PET)-computed tomography (CT) in a UK population.
MATERIALS AND METHODS: This was a retrospective review of PET-CT examinations performed to stage radiologically suspected T1 part-solid lung adenocarcinoma (n=58) from two different centres. Rates of detection of nodal and metastatic disease, change in management, and final patient outcome were recorded.
RESULTS: PET-CT changed the stage in one patient from N0 to N1. It did not change final management in any patient.
CONCLUSIONS: In this UK population, PET-CT had minimal additional diagnostic benefit in staging patients with T1 part-solid lung adenocarcinoma. Especially given its cost, the inclusion of PET-CT for this indication in guidelines should be reviewed.
引用
- Pencharz, Modi, Bandyopadhyay, et al. Absence of clinical benefit of FDG PET-CT in staging T1 part-solid lung adenocarcinoma. Clin Radiol. 2021. PMID: 34953570. doi:10.1016/j.crad.2021.11.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。